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Abstract
Background: Estrogen receptor β (ERβ) is expressed in the majority of invasive breast cancer cases, irrespective of
their subtype, including triple-negative breast cancer (TNBC). Thus, ERβ might be a potential target for therapy of
this challenging cancer type. In this in vitro study, we examined the role of ERβ in invasion of two triple-negative
breast cancer cell lines.
Methods: MDA-MB-231 and HS578T breast cancer cells were treated with the specific ERβ agonists ERB-041,
WAY200070, Liquiritigenin and 3β-Adiol. Knockdown of ERβ expression was performed by means of siRNA
transfection. Effects on cellular invasion were assessed in vitro by means of a modified Boyden chamber assay.
Transcriptome analyses were performed using Affymetrix Human Gene 1.0 ST microarrays. Pathway and gene
network analyses were performed by means of Genomatix and Ingenuity Pathway Analysis software.
Results: Invasiveness of MBA-MB-231 and HS578T breast cancer cells decreased after treatment with ERβ agonists
ERB-041 and WAY200070. Agonists Liquiritigenin and 3β-Adiol only reduced invasion of MDA-MB-231 cells. Knockdown
of ERβ expression increased invasiveness of MDA-MB-231 cells about 3-fold. Transcriptome and pathway analyses
revealed that ERβ knockdown led to activation of TGFβ signalling and induced expression of a network of genes
with functions in extracellular matrix, tumor cell invasion and vitamin D3 metabolism.
Conclusions: Our data suggest that ERβ suppresses invasiveness of triple-negative breast cancer cells in vitro.
Whether ERβ agonists might be useful drugs in the treatment of triple-negative breast cancer, has to be evaluated
in further animal and clinical studies.
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Background
Ten to twenty percent of all breast cancers are triple-
negative breast cancers (TNBC) [1]. This breast cancer
subgroup lacks expression of estrogen receptor alpha
(ERα) and progesterone receptor (PR) as well as human
epidermal growth factor receptor 2 (HER2) amplifica-
tion. TNBCs are more frequent in younger patients and
tumors are generally larger in size. Moreover, TNBCs
are more aggressive, of higher grade and often have
lymph node involvement at diagnosis [1, 2]. As patients
with TNBC do not benefit from targeted therapies with
tamoxifen or trastuzumab [3–5], they have a poorer
prognosis and a higher rate of distant recurrence than
women with other breast cancer subtypes [2, 6]. Less
than one third of women with metastatic TNBC survive
5 years, and almost all die of their disease despite adju-
vant chemotherapy [6]. Most of TNBCs can be classified
as basal-like either by immunohistochemistry or by
correlation to the intrinsic molecular breast cancer
subtypes [7–9]. Basal-like tumors express markers of
the myoepithelium of the normal mammary gland, like
epidermal growth factor receptor (EGFR), p63 and the
basal cytokeratins CK14, CK5/6 and CK17 [10, 11].
In contrast to estrogen receptor α (ERα), the second
estrogen receptor, ERβ has been shown to be expressed
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in all molecular subtypes of breast cancer, including
60% of basal-like tumors [12]. Thus, ERβ could be an
interesting therapy target for patients with TNBC. ERβ
has been suggested to act as a tumor-suppressor in
breast tissue, because its expression declines during
carcinogenesis, its knockdown increased proliferation
of mammary epithelial and breast cancer cells, whereas
its overexpression inhibited tumor cell proliferation
[13–17]. Previously, ERβ status has been reported to
affect clinical outcome of TNBC [18]. However, the role of
ERβ in regulation of breast cancer cell invasiveness is only
beginning to be understood. Previously, ERβ has been re-
ported to enhance adhesion of ERα-positive breast cancer
cells by increase of integrin expression [19]. A recent
study reported that ERβ was able to repress epithelial to
mesenchymal transition and invasion of basal-like breast
cancer cells by destabilizing EGFR [20].
In this study, we further approached the role of ERβ in
invasiveness of TNBC cells. We knocked down ERβ in
TNBC cells and performed transcriptome and gene net-
work analyses to elucidate, whether genes with functions
in tumor cell invasion would be regulated. Additionally,
we examined whether treatment with ERβ agonists
would affect invasiveness of TNBC cell lines in vitro.
Methods
Material
Phenol red-free DMEM culture medium was obtained
from Invitrogen (Karlsruhe, Germany), FCS was pur-
chased from PAA (Pasching, Austria). MDA-MB-231
and HS578T breast cancer cells were obtained from
American Type Culture Collection (Manassas, USA).
RNeasy Mini Kit was obtained from Qiagen (Hilden,
Germany). Transfectin reagent was obtained from
BioRad (Hercules, USA). OptiMEM medium were pur-
chased at Invitrogen (Karlsruhe, Germany). ESR2 and
control siRNAs were from Ambion (Life Technologies,
USA). Serum Replacement 2 (SR2) cell culture supple-
ment was from Sigma-Aldrich (Deisenhofen, Germany).
ERβ agonists ERB-041 and WAY-200070 were from
Tocris (Bristol, UK). 5α-androstane-3β, 17β-diol (3β-
Adiol) was from Sigma (Deisenhofen, Germany) and
Liquiritigenin from Extrasynthese (Lyon, France).
Cell culture, transfection and proliferation assays
MDA-MB-231 and HS578T cells were maintained in
DMEM/F12 medium supplemented with 10% FCS. Cells
were cultured with 5% CO2 at 37 °C in a humidified in-
cubator. For transfection, 4 × 105 cells per well of a 6-
well dish were seeded in DMEM/F12 containing 10%
FCS. The next day, 2 ml fresh culture medium was
added to the cells, transfection solution was prepared in
OptiMEM medium (Invitrogen) using 5 μl Transfectin
reagent (BioRad) and a mix of three ESR2 siRNAs (10
nM each) (or 10 nM of siRNA specific for CYP24A1,
CXCL14 or negative control siRNA) and was added to
the cultured cells. The siRNA mix contained three dif-
ferent ESR2-specific Silencer siRNAs (siRNA IDs
145909, 145910, 145911, Ambion), targeting exons 1, 2
and 3 of ESR2 mRNA. For knockdown of CYP24A1 and
CXCL14, further Silencer siRNAs were used (siRNA IDs
106233 and 137806, respectively, Ambion). As a negative
control, Silencer Negative control siRNA #1 (Ambion)
was used. Gene knockdown of ESR2, CYP24A1 and
CXCL14 was verified by means of Western blot analysis
72 h after siRNA treatment as described below. For cell
proliferation assays, cells cultured in DMEM/F12 supple-
mented with 10% FBS were seeded in 96-well plates in
triplicates (1000 cell/well). On days 0, 2, 3 and 4 relative
numbers of viable cells were measured using the fluori-
metric, resazurin-based Cell Titer Blue assay (Promega)
according to the manufacturer’s instructions at 560Ex/
590Em nm in a Victor3 multilabel counter (PerkinElmer,
Germany). Cell growth was expressed as percentage of
day 0. Growth data were statistically analyzed by the
Kruskal–Wallis one-way analysis of variance.
Invasion assays
Tumor cell invasion was measured by assessment of
breast cancer cell invasion through an artificial basement
membrane using the 24-well Cultrex BME cell invasion
assay (Trevigen, USA), a modified Boyden-chamber
transwell assay with 8 μm pore size, according to the
manufacturer’s instructions. BME (basement membrane
extract) is a soluble form of basement membrane puri-
fied from Engelbreth-Holm-Swarm (EHS) tumor, mainly
consisting of laminin, collagen IV, entactin, and heparin
sulfate proteoglycan. Briefly, 100 μl ice-cold liquid BME
extract (10 mg/ml) was placed on top of the insert mem-
branes and polymerized at 37 °C over night to form a
reconstituted basement membrane gel of about 3 mm
thickness. 50000 MDA-MB-231 or HS578T cells (plus/
minus ERβ agonists, calcitriol or CXCL14 chemokine)
or the same number of cells previously transfected with
siRNA specific for ESR2, CYP24A1 or CXCL14, serum
starved in SR2 medium, were seeded the day after treat-
ment (or 2 days after treatment with the ERβ agonists)
on top of the BME coated inserts. The lower compart-
ment was filled with 600 μl of DMEM-F12 supple-
mented with 10% FCS as a chemoattractant. After 48 h
of invasion in a humidified incubator with 5% CO2 at
37 °C, relative numbers of cells invaded into the bottom
chamber were relatively quantified using the fluorimetric
Cell Titer Blue assay (Promega) as described above. As
negative controls, samples without chemoattractant were
measured. Cell proliferation used for calculation of the
corrected invasion rate was determined in parallel exper-
iments using the same assay.
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RNA preparation and real-time RT-PCR
Total RNA was isolated from 30 to 80 mg frozen tissue
or from cell lines (106 cells) by means of Trizol reagent
(Invitrogen, Karlsruhe, Germany) according to manufac-
turer’s protocol. RNA purity and concentration was ana-
lyzed by spectrophotometry. From each sample, 500 ng
of total RNA was reverse transcribed to cDNA using 40
units of M-MLV Reverse Transcriptase and RNasin
(Promega, Mannheim, Germany) with 80 ng/μl random
hexamer primers (Invitrogen, Karlsruhe, Germany) and
10 mM dNTP mixture (Fermentas, St. Leon-Rot,
Germany) according to the manufacturer’s instructions.
After reverse transcription, specific transcript levels
were determined by real-time PCR. For this purpose,
4 μl of cDNA were amplified using LightCycler® FastStart
DNA MasterPLUS SYBR Green I (Roche Diagnostics
GmbH, Mannheim, Germany) and 5 mM of each primer
(Additional file 1: File S1). Oligonucleotides (Metabion,
Planegg-Martinsried, Germany) were designed intron-
spanning to avoid genomic contaminations.
Real-time PCRs were carried out in a LightCycler® 2.0
Instrument (Roche, Mannheim, Germany) under the fol-
lowing conditions: initial denaturation at 95 °C for
15 min, followed by 45 cycles with 10 s denaturation at
95 °C, 5 s annealing at 60 °C and 12 s extension at 72 °C.
The PCR program was completed by a standard melting
curve analysis. Negative controls were prepared by adding
distilled water instead of cDNA. To verify the identity of
the PCR products, they were initially analyzed by electro-
phoresis in 1.5% agarose gels and stained with ethidium
bromide. After size check, each PCR product was then
purified using the “QIAquick Gel Extraction Kit” (Qiagen,
Hilden, Germany), following the manufacturer’s protocol
and verified by sequencing (Eurofins MWG Operon,
Ebersberg, Germany). In all RT-PCR experiments, a
190 bp β-actin fragment was amplified as reference gene
using intron-spanning primers actin-2573 and actin-2876.
Data from two independent PCR experiments per sample
were analyzed using the comparative ΔΔCT method [21]
calculating the difference between the threshold cycle
(CT) values of the target and reference gene of each sam-
ple and then comparing the resulting Δ CT values between
different samples.
Western blot analysis
Seventy-two hours after transfection, MDA-MB-231
were lysed in RIPA buffer (1% (v/v) Igepal CA-630, 0.5%
(w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl
sulphate (SDS) in phosphate-buffered solution (PBS)
containing aprotonin and sodium orthovanadate. Ali-
quots containing 10 μg of protein were resolved by 10%
(w/v) SDS–polyacrylamide gel electrophoresis, followed
by electrotransfer to a PVDF hybond (Amersham, UK)
membrane. Immunodetection was carried out using
monoclonal ESR2 antibody 14C8 (1:500), (ab288, Abcam,
Germany), CYP24A1 polyclonal antibody (ab175976,
Abcam, Germany) diluted 1:300 in PBS containing 5%
skim milk (w/v), polyclonal CXCL14 antibody (1:250)
(ab36622, Abcam, Germany), monoclonal tenascin-c anti-
body [EPR4219] (1:500) (ab108930, Abcam, Germany),
polyclonal MMP13 antibody (1:1000) (ab39012, Abcam)
and β-actin antibody (1:500) (ab8226, Abcam) followed by
horseradish peroxidase conjugated secondary antibody
(1:20000) which was detected using chemiluminescence
(ECL) system (Amersham, Buckinghamshire, UK). The
Western blot results from three independent protein
isolations were densitometrically analyzed (ImageJ, NIH)
and expressed in percentage of cell transfected with nega-
tive control siRNA.
GeneChipTM microarray assay
Processing of four RNA samples (two biological repli-
cates from MDA-MB-231 cells transfected with ESR2
siRNAs or control siRNA as described above) was per-
formed at the local Affymetrix Service Provider and
Genomics Core Facility, “KFB - Centre of Excellence
for Fluorescent Bioanalytics” (Regensburg, Germany;
www.kfb-regensburg.de). Sample preparation for micro-
array hybridization was carried out as described in the
Affymetrix GeneChip® Whole Transcript (WT) Sense Tar-
get Labelling Assay manual. 300 ng of total RNA were
used to generate double-stranded cDNA. Subsequently
synthesized cRNA (WT cDNA Synthesis and Amplifica-
tion Kit, Affymetrix) was purified and reverse transcribed
into single-stranded (ss) DNA. After purification, the
ssDNA was fragmented using a combination of uracil
DNA glycosylase (UDG) and apurinic/apyrimidinic endo-
nuclease 1 (APE 1). Fragmented DNA was labelled with
biotin (WT Terminal Labelling Kit, Affymetrix), and
2.3 μg DNA were hybridized to the GeneChip Human
Gene 1.0 ST Array (Affymetrix) for 16 h at 45 °C in a ro-
tating chamber. Hybridized arrays were washed and
stained in an Affymetrix Washing Station FS450 using
preformulated solutions (Hyb, Wash & Stain Kit, Affyme-
trix), and the fluorescent signals were measured with an
Affymetrix GeneChip® Scanner 3000-7G.
Microarray data analysis
Summarized probe signals were created by using the
RMA algorithm in the Affymetrix GeneChip Expression
Console Software and exported into Microsoft Excel.
Data was then analysed using Ingenuity IPA Software
(Ingenuity Systems, Stanford, USA) and Genomatix Path-
way Analysis software (Genomatix, Munich, Germany).
Genes with more than 2-fold changed mRNA levels after
ERβ knockdown in both biological replicates were con-
sidered to be differentially expressed and were included
in the analyses.
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Results
Characterization of the employed breast cancer cell lines
First we tested receptor expression of MDA-MB-231
and HS578T cells to characterize the cell culture models
employed in this study. For comparison we included
MCF-7 cells, known to express ERs and PR and also
SK-BR3 cells, which overexpress HER2. MDA-MB-231
and HS578T cells did only express extremely low or
even undetectable mRNA levels of ERα, PR or HER2,
as expected from triple-negative breast cancer cells. In
contrast, they strongly expressed EGFR mRNA. ERβ
transcript levels were higher in MDA-MB-231 cells
than in MCF-7 and HS578T cells (Additional file 2:
Figure S2).
Effect of ERβ agonists on invasion of MDA-MB-231 and
HS578T cells
The employed cell lines MDA-MB-231 and HS578T had
a comparable invasion capacity (Additional file 3: Figure
S3). To examine the role of ERβ in invasion of TNBC
cells, we first treated both cell lines with a panel of four
ERβ agonists. Treatment with all ERβ agonist decreased
invasion of MDA-MB-231 cells and, to a lesser extent,
of HS578T cells. While we tested agonist concentrations
from 10 nM to 10 μM, only treatment with 10 nM of
ERβ agonists had a statistically significant effect on inva-
sion of MDA-MB-231 cells. Ten nanometre of ERB-041
decreased invasion down to 39.8% (p < 0.05), 10 nM of
WAY200070 reduced invasion down to 37.1% (p < 0.05),
10 nM of 3β-Adiol down to 42.8% (p < 0.05) and the
same concentration of Liquiritigenin decreased invasion
down to 53.5% (p < 0.05). In contrast, invasiveness of
HS578T cells expressing lower levels of ERβ was only
inhibited by the highest concentration of ERB-041 and
WAY-200070 (10 μM), but was not affected by the other
two agonists (Fig. 1). None of the ERβ agonists tested
did affect proliferation of these cell lines in a significant
manner (data not shown).
Fig. 1 Effect of different ERβ agonists on invasion of triple negative MDA-MB-231 and HS578T breast cancer cells. Cellular invasion through a
3 mm gel of reconstituted basement membrane was determined using a modified Boyden chamber. Cells were pre-treated for 48 h with the
indicated concentrations of ERβ agonists, seeded on top of the basement membrane gel in the presence of the same agonist concentrations,
and invasion was determined after further 48 h as described in the Materials and Methods section. Values are expressed in percent of invasion
of vehicle-treated cells. *p < 0.05 vs vehicle control. (n = 4). (Kruskal-Wallis H-test with Bonferroni post-hoc test)
Fig. 2 Effect of ERβ knockdown on invasion of MDA-MB-231 cells. a
Effect of treatment with ESR2 siRNA for 72 h on ERβ protein expression
in MDA-MB-231 cells as assessed by Western blot analysis. b Effect of
ERβ knockdown on cellular invasion of MDA-MB-231 cells through a
basement membrane in vitro. The day after transfection, cells were
seeded on top of a 3 mm reconstituted basement membrane gel,
and invasion was determined after further 48 h as described in the
Materials and Methods section. Values are expressed in percentage
of invasion of control-transfected cells. *vs. negative control siRNAs
(n = 3) (unpaired t‑test, two‑tailed)
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Table 1 Effect of an ERβ knockdown on transcriptome of MDA-MB-231 cells as assessed by means of Affymetrix Human Gene 1.0 ST
arrays. Shown are all genes exhibiting more than 2-fold change with a p-value <0.05 (n = 2)
Fold change p-value Gene symbol Gene name
Upregulated genes
4,82 0,01331 CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1
4,23 0,00240 CXCL14 chemokine (C-X-C motif) ligand 14
3,80 0,02136 ENC1 ectodermal-neural cortex 1 (with BTB-like domain)
3,71 0,01270 DKK1 dickkopf 1 homolog (Xenopus laevis)
3,38 0,00778 HIPK3 homeodomain interacting protein kinase 3
3,36 0,02378 TRIM49B tripartite motif containing 49B
3,21 0,02620 MMP13 matrix metallopeptidase 13 (collagenase 3)
3,04 0,00236 ARRDC3 arrestin domain containing 3
2,98 0,00932 TNC tenascin C
2,82 0,04833 KRT4 keratin 4
2,82 0,02350 FRG2B FSHD region gene 2 family, member B
2,74 0,04198 LOC100506966 uncharacterized LOC100506966
2,72 0,00962 AQP1 aquaporin 1 (Colton blood group)
2,62 0,01339 MFAP5 microfibrillar associated protein 5
2,61 0,03991 ANGPT1 angiopoietin 1
2,50 0,02567 MAPK8IP1 mitogen-activated protein kinase 8 interacting protein 1
2,49 0,00499 DEPTOR DEP domain containing MTOR-interacting protein
2,48 0,04712 IGFBP5 insulin-like growth factor binding protein 5
2,43 0,01205 NPNT nephronectin
2,41 0,01544 C12orf53 chromosome 12 open reading frame 53
2,37 0,03051 HSPA2 heat shock 70 kDa protein 2
2,36 0,02207 PLLP plasmolipin
2,36 0,02959 SLC47A2 solute carrier family 47, member 2
2,35 0,01648 CRIP1 cysteine-rich protein 1 (intestinal)
2,33 0,00857 CNIH2 cornichon homolog 2 (Drosophila)
2,30 0,00344 TGFB2 transforming growth factor, beta 2
2,27 0,02260 CACNG4 calcium channel, voltage-dependent, gamma subunit 4
2,27 0,02987 CYP4F2 cytochrome P450, family 4, subfamily F, polypeptide 2
2,26 0,02720 MTRNR2L2 MT-RNR2-like 2
2,25 0,01804 TRIM53AP tripartite motif containing 53A, pseudogene
2,20 0,00819 TP53INP1 tumor protein p53 inducible nuclear protein 1
2,19 0,02351 CLEC2L C-type lectin domain family 2, member L
2,19 0,00476 DRAM1 DNA-damage regulated autophagy modulator 1
2,19 0,00903 TRIM49L1 tripartite motif containing 49-like 1
2,19 0,00903 TRIM49L1 tripartite motif containing 49-like 1
2,16 0,02128 PTGER4 prostaglandin E receptor 4 (subtype EP4)
2,13 0,01616 FLRT3 fibronectin leucine rich transmembrane protein 3
2,12 0,02280 DPYSL2 dihydropyrimidinase-like 2
2,12 0,03376 ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B1
2,10 0,04897 FAM102B family with sequence similarity 102, member B
2,10 0,00007 CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15
2,10 0,00777 PTBP3 polypyrimidine tract binding protein 3
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Effect of an ERβ knockdown on invasiveness of breast
cancer cells
We now wanted to find out whether knockdown of
ERβ would in turn be able to induce breast cancer
cell invasion. Given that MDA-MB-231 cells turned
out to be much more sensitive to ERβ agonists, and
had a higher expression of this receptor, we chose
this cell line for knockdown of ERβ. Seventy-two
hours after transfection with ERβ-specific siRNAs, a
maximum suppression of total ERβ transcript levels
down to 11.8% was observed (data not shown).
Western blot analysis confirmed knockdown of ERβ
protein expression after 72 h of transfection (Fig. 2a).
Using these ERβ knockdown cells together with cells
transfected with negative control siRNA, we per-
formed further in vitro invasion assays to examine
the action of this gene in TNBC cell invasion. To be
sure that ERβ expression was significantly reduced
during the whole invasion assay, MDA-MB-231 cells
were seeded onto the basement membrane 24 h after
siRNA transfection, and invasion was measured after
further 48 h. MDA-MB-231 cells transfected with
ERβ siRNA showed an about 3-fold higher invasion
level than cells treated with negative control siRNA
(Fig. 2b). With regard to cell proliferation, only
knockdown of ERβ in MDA-MB-231 cells, but not
in HS578T cells significantly accelerated proliferation
(Additional file 4: Figure S4).
Table 1 Effect of an ERβ knockdown on transcriptome of MDA-MB-231 cells as assessed by means of Affymetrix Human Gene 1.0 ST
arrays. Shown are all genes exhibiting more than 2-fold change with a p-value <0.05 (n = 2) (Continued)
2,09 0,02408 TGFB1 transforming growth factor, beta 1
2,07 0,04539 NID1 nidogen 1
2,07 0,03066 IGFBP7 insulin-like growth factor binding protein 7
2,07 0,00551 LOC100509553 ETS domain-containing protein Elk-1-like
2,05 0,03765 PPP1R3C protein phosphatase 1, regulatory subunit 3C
2,04 0,00619 FOXN1 forkhead box N1
2,03 0,01322 GPR56 G protein-coupled receptor 56
2,03 0,01062 SFN stratifin
2,02 0,00706 CYTL1 cytokine-like 1
2,02 0,00298 PRICKLE1 prickle homolog 1 (Drosophila)
2,01 0,00401 MET met proto-oncogene (hepatocyte growth factor receptor)
2,00 0,02964 MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11
2,00 0,01646 LOX lysyl oxidase
Downregulated genes
−2,00 0,01776 GK5 glycerol kinase 5 (putative)
−2,01 0,00969 KPNA5 karyopherin alpha 5 (importin alpha 6)
−2,04 0,02721 TMC7 transmembrane channel-like 7
−2,05 0,04973 C4orf27 chromosome 4 open reading frame 27
−2,06 0,01484 IARS isoleucyl-tRNA synthetase
−2,08 0,00684 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31 kDa
−2,11 0,03884 JHDM1D jumonji C domain containing histone demethylase 1 homolog D (S. cerevisiae)
−2,13 0,01199 ODC1 ornithine decarboxylase 1
−2,19 0,03799 MCMDC2 minichromosome maintenance domain containing 2
−2,22 0,04674 GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
−2,23 0,01299 MIR320D2 microRNA 320d-2
−2,24 0,00323 DICER1 dicer 1, ribonuclease type III
−2,29 0,02510 RN5S505 RNA, 5S ribosomal 505
−2,38 0,02642 LINC00243 long intergenic non-protein coding RNA 243
−2,55 0,04468 MTX3 metaxin 3
−2,62 0,00555 SEMA3D sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D
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Effect of an ERβ knockdown on transcriptome of
MDA-MB-231 cells
To elucidate the molecular mechanisms underlying the
effect of this receptor on TNBC invasion, we examined
the effect of an ERβ knockdown on transcriptome of
MDA-MB-231 cells. For this purpose, we compared the
transcriptome of these knockdown cells with MDA-
MB-231 cells transfected with negative control siRNA
by DNA microarray analysis (Affymetrix Human Gene
1.0 ST Arrays).
Transcript levels of 55 genes were found to be induced
more than 2-fold, whereas 16 genes were more than 2-
fold decreased in MDA-MB-231 cells transfected with
ERβ siRNA (Table 1). Additional Western Blot analyses
were performed which were able to corroborate upregu-
lation of CYP24A1, MMP13 and TNC on the protein
level in ERβ knockdown cells (Fig. 3).
Microarray data were then processed using Genomatix
Software Suite (Genomatix Software, Munich, Germany)
and Ingenuity Pathway Analysis software (IPA, Ingenuity
Systems, USA). With regard to localization in cellular
components, Genomatix software revealed that as
much as 20 of the upregulated genes were associated
with the Gene Ontology (GO) term extracellular region,
among them five genes coding for extracellular matrix
proteins and ten genes with known functions in the
extracellular matrix (Table 2). Analysis of the data with
regard to the GO domain molecular function revealed
that beside proteins TGFB1 and B2 being ligands for
transforming growth factor receptors, other regulated
genes coded for proteins being able to bind to fibronec-
tin, lipoprotein particle receptors, insulin-like growth
factor receptors or cytokine receptors. With regard to
biological processes, the regulated genes were found to
be associated with assembly or organization of the
extracellular matrix, but also with tissue morphogen-
esis, apoptosis, cell adhesion and migration. A set of
genes was known to be regulated in response to steroid
hormones like estrogens (Table 2). By means of Geno-
matix Pathway Analysis software, the genes regulated
by ERβ knockdown in MDA-MB-231 cells could be
connected by a network of genes known to be regulated
by TGFB1 (Fig. 4).
Further analyzes of the microarray data by means of
Ingenuity Pathway Analysis software (IPA, Ingenuity
Systems) generated a second gene network including
involvement of estrogen signaling (Fig. 5).
Fig. 3 Western blot analysis of genes exhibiting elevated transcript
levels after ERβ knockdown in MDA-MB-231 cells. Analyses were
performed using specific antibodies against MMP13, TNC and
CYP24A1 and β-actin as a loading control. Shown are representative
blots and the means of three experiments (n = 3). *vs. control siRNA
(unpaired t‑test, two‑tailed)
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Role of CYP24A1 and CXCL14 in invasion of MDA-MB-231
breast cancer cells
Given that CYP24A1 and CXCL14 were the top upreg-
ulated genes, we further examined their role in MDA-
MB-231 breast cancer cell invasion. For this purpose,
we knocked down their expression by means of siRNA
transfection and examined the effect on invasion of
MDA-MB-231 cells. Three days after siRNA transfec-
tion, specific protein levels were reduced by 89.4%
(CXCL14, p < 0.01), or 82.1% (CYP24A1, p < 0.01), re-
spectively (Fig. 6a, upper panel). Three days after
siRNA transfection, knockdown of CYP24A1 gene re-
sulted in significant inhibition of invasiveness down to
45.6% (p < 0.01), and knockdown of CXCL14 expression
decreased MDA-MB-231 cell invasion down to 41.0%
(Fig. 6a, lower panel).
To corroborate the data generated by knockdown of
CYP24A1 and CXCL14, we treated this cell line with
calcitriol or CXCL14 chemokine the day before and
during the invasion assay. Calcitriol (10 nM) reduced
invasion of MDA-MB-231 breast cancer cells by 59.8%,
and CXCL14 (10 ng/ml) increased their invasiveness up
to 151.9% (Fig. 6b).
Discussion
In this study, invasiveness of TNBC cells in vitro was
found to decrease after treatment with ERβ agonists,
but increased after knockdown of this gene. The results
of our study clearly suggest that ERβ might be able to
suppress invasion of certain breast cancer cells in an
ERα-independent manner.
Although the role of ERβ in breast cancer is only
beginning to be understood, an increasing amount of
evidence suggests that this receptor might exert tumor-
suppressor functions [13–17]. If this is the case, activa-
tion of ERβ by specific agonists might be a feasible
treatment option for breast cancer. In this study, we
tested four ERβ agonists which have been reported to
bind preferentially to this receptor, but only to a much
smaller extent to ERα. Given that the employed cell
lines were ERα-negative, the observed agonist effects
most likely were mediated by ERβ.
The dihydrotestosterone metabolite 5α-androstane-3β,
17β-diol (3β-Adiol) is an androgen derivative which does
not bind androgen receptors, but efficiently binds ERβ,
and its serum concentration is known to decline in the
second half of life [22]. 3β-Adiol acts as a physiological
ERβ-activator in different tissues [23, 24]. In line with
our data, 3β-Adiol has been reported to inhibit cellular
migration and epithelial-mesenchymal transition of pros-
tate cancer cells as well as to reduce tumor progression
[22, 25]. ERB-041 and WAY-200070 are highly specific
synthetic ERβ agonists [26, 27]. ERB-041 is known to
display a more than 200-fold selectivity for ERβ than for
Table 2 Genes with more than 2-fold regulation after knockdown of ERβ: Gene ontology (GO)
GO-Term GO-Term id P-value List of observed genes
A. GO Cellular components
Extracellular matrix part GO:0044420 4,91E-04 MFAP5, TNC, MMP13, LOX, NID1
Extracellular region GO:0005576 3,71E-05 MFAP5, AQP1, TNC, IGFBP7, NPNT, MMP13, LOX, CXCL14,
TNFSF15, ANGPT1, TGFB2, MTRNR2L2, FLRT3, SEMA3D,
TGFB1, NID1, DKK1, CYTL1, IGFBP5, SFN
Extracellular matrix GO:0031012 2,66E-06 MFAP5, TNC, IGFBP7, NPNT, MMP13, LOX, TGFB2,
FLRT3, TGFB1, NID1
B. GO Molecular functions
Type II transforming growth factor beta receptor binding GO:0005114 2,73E-04 TGFB2, TGFB1
Fibronectin binding GO:0001968 2,16E-03 MMP13, IGFBP5
Lipoprotein particle receptor binding GO:0070325 2,16E-03 MMP13, DKK1
Insulin-like growth factor binding GO:0005520 3,74E-03 IGFBP7, IGFBP5
Cytokine receptor binding GO:0005126 6,89E-03 CXCL14, TNFSF15, TGFB2, TGFB1
C. GO Biological processes (excerpt)
Extracellular matrix assembly GO:0085029 4,84E-04 LOX, TGFB1
Tissue morphogenesis GO:0048729 6,67E-04 TNC, TGFB2, TGFB1, PRICKLE1, DKK1, IGFBP5, DICER1
Regulation of apoptotic process GO:0042981 9,83E-04 AQP1, MLLT11, DEPTOR, TAF9B, ANGPT1, TP53INP1,
TGFB2, TGFB1, MAPK8IP1, DICER1, HIPK3, SFN
Extracellular matrix organization GO:0030198 1,43E-03 LOX, TGFB2, TGFB1, NID1
Response to steroid hormone stimulus GO:0048545 5,18E-03 AQP1, MMP13, LOX, TGFB2, TGFB1
Cell adhesion GO:0007155 6,37E-03 TNC, IGFBP7, NPNT, ANGPT1, GPR56, TGFB2, FLRT3, TGFB1, NID1
Regulation of cell migration GO:0030334 7,78E-03 PTGER4, ANGPT1, TGFB2, TGFB1, IGFBP5
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ERα (EC50 ERβ = 2 nM), WAY-200070 still has a 68-fold
higher selectivity for ERβ than for ERα (EC50 ERβ = 2 nM)
[28]. Liquiritigenin is a plant-derived flavonoid from lic-
orice root, which acts as a highly selective agonist of ERβ
(EC50 ERβ = 36.5 nM) [29]. Previously, Liquiritigenin and
3β-Adiol have been reported to inhibit proliferation of
different breast cancer cell lines except of TNBC cell line
MDA-MB-231, while the agonists WAY200070 and
ERB-041 did not affect proliferation of ERα-positive
breast cancer cells lines [30, 31].
The fact that invasiveness of HS578T cells was only
sensitive to high ERβ agonist concentrations might be
explained by the significantly lower ERβ expression
levels observed in this cell line. Our observation that
only lower concentrations of the ERβ agonists were able
to reduce invasion of MDA-MB-231 cells is in line with
the agonists EC50 values for ERβ, which all are in the
low nanomolar range. Pathway analyses of the micro-
array data revealed induction of several genes coding for
components or regulators of the extracellular matrix
after knockdown of ERβ in MDA-MB-231 cells. Many
genes regulated after treatment with ERβ siRNA could
be identified to exert important functions in cell adhe-
sion, cell migration and tumor cell invasion. Most of
these genes are known targets of TGFβ like MMP13,
TNC, IGFBP7 and LOX [32–34]. Due to the assessed
transcriptome changes and upregulation of TGFB1 and
TGFB2 itself, it is suggested that knockdown of ERβ re-
sulted in activation of TGFβ1/2 signaling, which resulted
in induction of genes with known functions in extracel-
lular matrix and tumor cell invasion (Fig. 5). TGFβ sig-
naling previously has been shown to induce motility
and invasion of breast cancer cells [35–40].
TNC, whose expression was shown to be significantly
induced after knockdown of ERβ both on the mRNA
and protein level, is known to exert important functions
in tumor cell invasion. TNC gene codes for the large
extracellular matrix glycoprotein tenascin-c that shows
prominent stromal expression in many solid tumors and
has been reported to promote invasion of tumor cells
of different origin, including breast cancer cells by
matrix metalloproteinase-dependent and -independent
mechanisms [41–47].
MMP13 gene, the expression of which was induced
more than 3-fold after ERβ knockdown, codes for matrix
metalloproteinase 13 (collagenase 3), a protease originally
identified in breast carcinoma, which is also known to
promote tumor cell invasion and has been previously re-
ported as a molecular marker for transition of ductal car-
cinoma in situ lesions to invasive ductal carcinomas [48].
Fig. 4 Network of genes regulated after ERβ knockdown in MDA-MB-231 cells and cellular location of their gene products. In DNA microarray
analyses, the indicated genes were found to be induced more than 2-fold (p < 0.05) after ERβ knockdown, except the two genes marked with a
black arrow, which were down regulated at least 2-fold. * = protein with function in extracellular matrix. Dashed line: association of undefined type
due to co-citation of gene A and B; solid line with arrow: activation of gene B by gene A; solid line with rhombus: modulation of gene B by gene
A. This figure was created using Genomatix Pathway Analysis software (Genomatix, Munich, Germany)
Fig. 5 Network of genes induced after ERβ knockdown including
the known effects of 17 β-estradiol on their expression. Grey boxes:
up-regulated genes. Dashed line: regulation of expression, solid line:
(additionally) other forms of interactions. The figure was created by
means of Ingenuity Pathway Analysis software (Ingenuity Systems,
Redwood City, USA)
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The observed activation of CYP24A1 gene coding for
a mitochondrial enzyme which degrades 1,25-dihydroxy-
vitamin D3 into biologically inactive metabolites is an-
other key event triggered by ESR2 knockdown. The
complementary effects of CYP24A1 gene knockdown
and treatment with calcitriol on invasion we observed
corroborate the proposed key role of this gene in our
study. CYP24A1 antagonizes the antitumoral actions of
this vitamin and is known to be overexpressed in breast
cancer tissue [49, 50]. The observed upregulation of
CYP24A1 mRNA and protein after knockdown of ERβ is
proposed to be one important reason for the increase of
MDA-MB-231 cell invasiveness, because 1,25-dihydroxy-
vitamin D3 is known to reduce invasion, motility and
metastasis of cancer cells (reviewed in [51]). Though we
did not measure the exact concentration of 1,25-dihy-
droxyvitamin D3 in the fetal calf serum we used for cell
culture, it is well known that serum contains calcitriol.
Given that this vitamin is known to suppress expression
of tenascin-c, the upregulation of this ECM component
we found both on the mRNA and protein level most
probably is the consequence of the elevated CYP24A1
expression we observed [52].
The strongly induced chemokine CXCL14 is known to
exert both tumor-suppressive and tumor-promoting
effects in mammals. While it primarily acts as a chemo-
attractor for macrophages, dendritic cells and natural
killer cells, CXCL14 is also able to act as a pro-
tumorigenic factor. In line with our findings, CXCL14
has been previously reported to promote motility and
invasion of breast and prostate cancer cells and bone
metastasis of lung cancer cells [53–55]. CXCL14 has
previously been reported to be induced by steroid hor-
mones like progestin, but the mechanism linking ERβ
and CXCL14 remains to be elucidated [56].
Pathway analyzes finally generated a gene network which
might be able to at least partially elucidate the connection
between ERβ knockdown and the transcriptome changes
we observed (Fig. 6). Expression of the genes CYP24A1 and
MMP13 has previously been reported to be activated by
Fig. 6 Effect of CYP24A1, 1,25(OH)2D3 (calcitriol) and CXCL14 on
invasion of MDA-MB-231 cells. a Upper panel: Densitometrical
analysis of Western blot experiments examining protein expression
of the indicated genes 72 h after treatment with siRNA to CYP24A1
or CXCL14. Values are expressed in percentage of protein expression in
control-transfected cells (n = 3). Lower panel: Invasion of MDA-MB-231
cells determined 72 h after treatment with siRNA to CYP24A1
or CXCL14, in percentage of invasion of control-transfected cells
(n = 3). b Untransfected cells were treated with calcitriol (10 nM) or
recombinant CXCL14 (10 ng/ml) 48 h before and during invasion
assay. Cellular invasion was examined in vitro like described in the
Materials and Methods section. Values are expressed in percentage
of invasion of vehicle-treated cells (n = 3). *p < 0.01 vs. control
(unpaired t‑test, two‑tailed)
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estrogens [57, 58]. Thus, it is tempting to speculate that
repression of ERβ - knowing to act as an ERα antagonist in
certain settings - might increase estrogen-triggered expres-
sion of MMP13 and CYP24A1 mediated by ERα. Expres-
sion of TGFβ, a key molecule of the generated network is
also known to be regulated by estrogens, but this interaction
seems to be more complex. Whereas some studies
reported activation of TGFβ expression by estrogens,
others found inhibitory effects of this steroid hormone
particularly on expression of TGFB2 [59, 60]. Thus, the
molecular mechanisms underlying the observed activa-
tion of TGFβ-expression and -signaling triggered by
knockdown of ESR2 gene remain to be elucidated.
Conclusion
In conclusion, the observed effects of an ERβ knockdown
and of treatment with ERβ agonists on breast cancer cell
invasion were consistent and clearly suggest that this
receptor inhibited invasion of the employed TNBC cells in
vitro. Transcriptome and gene network analyses provided
molecular mechanisms which might underlie the observed
alteration of invasion. Whether ERβ agonists might be
suitable for treatment of triple-negative breast cancer, has
to be evaluated in further animal and clinical studies.
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